Department of Health and Social Care

The standard of training for doctors is the responsibility of the General Medical Council (GMC). The curricula for postgraduate specialty training are set by the Academy of Medical Royal Colleges for foundation training, and by individual royal colleges and faculties for specialty training. The GMC approves curricula and assessment systems for each training programme.

The Government will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan, including specialists across the full scope of National Health Service care. It will ensure that the NHS has the right people in the right places, with the right skills to care for patients, including those with Parkinson’s disease, when they need it. The 10 Year Workforce Plan will set out how we will deliver that change by making sure that staff are better treated, have better training, more fulfilling roles, and hope for the future.

We have set up a United Kingdom-wide Neuro Forum, facilitating formal, twice-yearly meetings across the Department, NHS England, the devolved administrations and health services, and the Neurological Alliances of all four nations. The new forum brings key stakeholders together to share learnings across the system and discuss challenges, best practice examples, and potential solutions for improving the care of people with neurological conditions, including Parkinson’s. The forum has identified areas for initial focus, including workforce, which featured as a key item on the agenda at the second meeting of the forum in September 2025.

The standard of training for doctors is the responsibility of the General Medical Council (GMC). The curricula for postgraduate specialty training are set by the Academy of Medical Royal Colleges for foundation training, and by individual royal colleges and faculties for specialty training. The GMC approves curricula and assessment systems for each training programme.

The Government will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan, including specialists across the full scope of National Health Service care. It will ensure that the NHS has the right people in the right places, with the right skills to care for patients, including those with Parkinson’s disease, when they need it. The 10 Year Workforce Plan will set out how we will deliver that change by making sure that staff are better treated, have better training, more fulfilling roles, and hope for the future.

We have set up a United Kingdom-wide Neuro Forum, facilitating formal, twice-yearly meetings across the Department, NHS England, the devolved administrations and health services, and the Neurological Alliances of all four nations. The new forum brings key stakeholders together to share learnings across the system and discuss challenges, best practice examples, and potential solutions for improving the care of people with neurological conditions, including Parkinson’s. The forum has identified areas for initial focus, including workforce, which featured as a key item on the agenda at the second meeting of the forum in September 2025.

Integrated care boards (ICBs) have existing contractual powers to manage activity by providers, which were enhanced in 2025/26 with central support for setting and managing activity. The NHS Standard Contract includes the ability to set Indicative Activity Plans (IAPs) to help providers and commissioners plan demand, capacity, and expenditure. While not binding, if activity exceeds the agreed plan, and therefore the funding agreed, an Activity Management Plan (AMP) can be agreed to bring activity back in line.

The provision and use of IAPs and AMPs is designed to deliver the activity levels required to achieve the goal of at least 65% of patients waiting no longer than 18 weeks for treatment by March 2026 whilst also living within financial budgets set for 2025/26.

Any planning assumptions based on waiting times need to support commissioners’ overall duties to the populations they serve and our waiting time targets, including our commitment to return to the 18-week standard. AMPs allow commissioners and providers to work together to manage elective activity within agreed performance and financial targets, all whilst working towards improving patient waiting times overall.

Patients have a legal right to choose where they go for their first appointment when referred to consultant-led care as an outpatient. ICBs are responsible for ensuring that their processes comply with the legal right to choose.

Since the publication of the Partnership Agreement in January 2025, the independent sector has delivered approximately 200,000 additional treatments compared to the same period last year.

Integrated care boards (ICBs) have existing contractual powers to manage activity by providers, which were enhanced in 2025/26 with central support for setting and managing activity. The NHS Standard Contract includes the ability to set Indicative Activity Plans (IAPs) to help providers and commissioners plan demand, capacity, and expenditure. While not binding, if activity exceeds the agreed plan, and therefore the funding agreed, an Activity Management Plan (AMP) can be agreed to bring activity back in line.

The provision and use of IAPs and AMPs is designed to deliver the activity levels required to achieve the goal of at least 65% of patients waiting no longer than 18 weeks for treatment by March 2026 whilst also living within financial budgets set for 2025/26.

Any planning assumptions based on waiting times need to support commissioners’ overall duties to the populations they serve and our waiting time targets, including our commitment to return to the 18-week standard. AMPs allow commissioners and providers to work together to manage elective activity within agreed performance and financial targets, all whilst working towards improving patient waiting times overall.

Patients have a legal right to choose where they go for their first appointment when referred to consultant-led care as an outpatient. ICBs are responsible for ensuring that their processes comply with the legal right to choose.

Since the publication of the Partnership Agreement in January 2025, the independent sector has delivered approximately 200,000 additional treatments compared to the same period last year.

NHS England is working to increase the size of the workforce trained to deliver thrombectomy so that 24/7 access is available across England by April 2026.

To achieve this NHS England is working with the General Medical Council in approving a credential to support neuroradiologists to conduct thrombectomy and increase the number of thrombectomies that can be delivered.

In addition, NHS England’s National Medical Director and National Clinical Director for Stroke has supported comprehensive stroke centers in England to improve quality and reduce variation in thrombectomy delivery.

I refer the Hon. Member to the answer I gave to the Hon. Member for Strangford on 26 January 2026 to Question 102753.

There are currently no plans to review publicly funded fellowship programmes for training overseas doctors. A range of international postgraduate medical training schemes operate across the National Health Service. These are governed by individual NHS trusts, medical royal colleges, the Academy of Medical Royal Colleges, and indirectly, NHS England, and the General Medical Council. These programmes are expected to be properly governed, provide value for money, and ensure fair treatment for all participants. We expect all NHS organisations to operate in line with these principles.

The Department’s financial wellbeing offer for its workforce includes access to a variety of advances including rental deposits and season ticket loans, as well as debt/budgeting advice and support through its Employee Assistance Programme.

The Department does not offer credit union membership via payroll deductions and has no current plans to introduce such arrangements. Of our executive agencies, only the UK Health Security Agency (UKHSA) has a general payroll deduction facility which could be used for such a purpose and the UKHSA includes details on its Financial Wellbeing page as to where employees can find further information on credit unions.

Higher education institutions are independent providers and are responsible for making their own decisions about course delivery and viability based on learner demand and provider capacity.

NHS England continues to work closely with the British Association of Prosthetics and Orthotics and education providers to maintain and strengthen training pathways, including apprenticeship routes, for learners into these courses.

Higher education institutions are independent providers and are responsible for making their own decisions about course delivery and viability based on learner demand and provider capacity.

NHS England continues to work closely with the British Association of Prosthetics and Orthotics and education providers to maintain and strengthen training pathways, including apprenticeship routes, for learners into these courses.

As of January 2026, total expenditure by the Department since July 2024 has been £69,384.94, inclusive of VAT, on X and zero on xAI.

As of January 2026, total expenditure by the Department since July 2024 has been £69,384.94, inclusive of VAT, on X and zero on xAI.

No assessment has been made of the potential impact of hospital parking charges on patients with long-term health conditions, or the introduction of free hospital parking for those patients.

It is important that the National Health Service is as accessible as possible to those that need it most. That is why the NHS already provides free hospital car parking to those in greatest need. This includes disabled blue badge holders, frequent outpatient attenders, and parents of children staying overnight. Some patients with long-term health conditions will therefore be provided free parking when included in these groups.

More widely, all NHS trusts are expected to follow the published NHS Car Parking Guidance. This states that car parking charges, where they exist, should be reasonable for the area, with further information available at the following link:

https://www.gov.uk/government/publications/nhs-patient-visitor-and-staff-car-parking-principles/nhs-patient-visitor-and-staff-car-parking-principles

Under our agreements with the European Union, European Free Trade Association countries and Switzerland, we make claims to European countries for National Health Service costs incurred by temporary visitors from those countries. Claims are made in arrears and take up to four years before they are fully settled.

The following table shows the position of European Health Insurance Card and Provisional Replacement Certificate claims for the last three financial years as of 31 March 2025:

These figures come from extracts from the NHS Business Services Authority’s claims processing database used by the Department for accounting purposes. Claims listed as withdrawn or paid have been settled whereas those listed as outstanding are still being agreed. We expect most outstanding claims to be settled in the United Kingdom’s favour.

This data excludes countries where NHS costs for temporary visitors are reimbursed based on a formula agreement which calculates costs from the number of visitors from that country to the UK. Further information is available at the following link:

https://www.gov.uk/government/publications/healthcare-eea-and-switzerland-arrangements-act-2019-annual-report-april-2021-to-march-2022/annual-report-on-payments-made-under-the-healthcare-eea-and-switzerland-arrangements-act-2019-april-2021-to-march-2022#financial-reimbursement-arrangements-of-current-agreements-listed-under-heeasa

The NHS England estates, commercial, and emergency preparedness, resilience, and response teams are undertaking an assessment of the provision of laundry services, in-house and out-sourced, in the National Health Service. This includes the NHS requirements for laundry services, available capacity, and the most efficient approach to their provision.

Appropriate information sharing is essential to delivering safe and effective health care. Improving this will enable enhanced quality of care and safety for patients and better informed clinical and care decision-making empowered by access to precise and comprehensive information.

NHS England has been supporting National Health Service trusts and foundation trusts in acquiring and developing the effectiveness of their electronic patient records and supporting them to reach an optimum level of digital maturity which will further reduce barriers to the sharing of information needed to treat patients.

By 2028, a new single patient record will end the need for patients to have to repeat their medical history when interacting with the NHS. By providing a complete, real-time view of patient information across regions and care settings, it will significantly improve clinical safety and performance.

The National Institute for Health and Care Excellence (NICE) aims to issue guidance on new medicines close to the time of licensing to ensure that patients benefit from rapid access to clinically and cost effective new medicines. The National Health Service in England is legally required to fund medicines recommended by NICE, normally within three months of final guidance, and cancer medicines are eligible for funding through the Cancer Drugs Fund from the point of a positive draft NICE recommendation, bringing forward patient access by up to five months.

Through the Life Sciences Sector Plan, we are improving alignment between Medicines and Healthcare products Regulatory Agency licensing and NICE guidance, helping medicines reach patients three to six months faster. This includes a coordinated pathway and integrated advice service for developers, launching in March 2026, to streamline regulatory and Health Technology Assessment processes and support timely patient access. The Life Sciences Sector Plan is published and available at the following link:

https://assets.publishing.service.gov.uk/media/688c90a8e8ba9507fc1b090c/Life_Sciences_Sector_Plan.pdf

The National Institute for Health and Care Excellence (NICE) is supporting the development of the modern service frameworks. NICE is also represented on the National Quality Board, along with other arm’s length bodies, that oversees the development of the modern service frameworks.

The National Institute for Health and Care Excellence (NICE) is currently assessing a number of technologies relevant to earlier cancer detection. These include capsule sponge tests to support detection of oesophageal cancer in primary care settings, and artificial intelligence (AI) tools to assist clinicians in identifying prostate and breast cancers from imaging. NICE is also considering potential evaluations, subject to evidence readiness and prioritisation, for technologies aimed at improving detection of endometrial cancer, and for AI-derived software to analyse chest x-rays for suspected lung cancer.

Timelines vary depending on the NICE programme through which a technology is assessed. For technologies evaluated through the Technology Appraisal programme, a positive recommendation creates a statutory funding requirement for National Health Service commissioners to make the treatment available within 90 days of final guidance publication.

NHS England is working closely with NICE and the Department to support the prioritisation for the Technology Appraisal programme. Should NICE recommend use after a Technology Appraisal, NHS England will support adoption and implementation through funding allocated across the multi-year Spending Review.

The Government is clear that innovation must narrow, not widen, health inequalities. Access to NICE-recommended technologies is a national entitlement, and where the statutory funding requirement applies it operates consistently across England, regardless of geography or care setting. NICE’s methods require consideration of equality impacts, and implementation support is designed to ensure that new detection technologies reach underserved groups and do not exacerbate existing disparities.

More broadly, the Government is taking a range of steps to ensure equitable access to earlier diagnosis. Our National Cancer Plan will drive up standards across England and tackle health inequalities head on. New cancer manuals will set out what good care looks like, with regional partnerships of health leaders and clinicians using data to drive improvements where services are falling short. The plan will also see new national standards, designed by clinicians, and better data, to inform and drive changes where they are most needed.

NHS England has published training modules about close relative marriage and genetic risk for midwives and health visitors. The training modules have been published for health professionals to access and there are no plans to publish them more widely. There are no plans to issue public facing guidance.

NHS Blood and Transplant (NHSBT) is responsible for blood services in England and is delivering initiatives to increase blood donations. These include:

• increasing awareness of donation through high-profile year-round campaigns including National Blood Week and World Blood Donor Day alongside the use of social media such as TikTok to reach additional audiences;
• using direct marketing, including phone calls, emails, and text messages, to encourage previous donors to book appointments and attend local sessions;
• increasing appointment availability and targeting communities where specific blood types are most needed through initiatives such as the Community Grants Programme, with further information available at the following link:
• https://www.nhsbt.nhs.uk/how-you-can-help/get-involved/community-grants-programme/; and
• increasing the number of successful donation appointments by: improving pre-donation haemoglobin (Hb) testing, with low‑Hb deferral rates having fallen since the full rollout of new testing in September 2025; implementing a pilot translation service to reduce language‑related deferrals; and enhancing vein-identification training using ethnicity-specific training arms to help staff recognise vein characteristics across different skin tones and body.

£1.9 billion has been invested to ensure all National Health Service trusts achieve baseline digital capability, and 95% of trusts will have implemented or upgraded their Electronic Patient Record system (EPR) by March 2026, with the remainder planning to implement after this.

Recent areas for focus have been EPR optimisation, working to improve functionality, efficiency and usability, and a new tiger team service in the Frontline Digitisation Support offer for 2025/26, which is available to provide trusts with rapid on-site support at critical points of their EPR journey. The team’s work will also inform practical guidance to help other trusts deploy successfully and realise the benefits of digitisation.

NHS England is continuing to conduct digital maturity assessments to support local systems and trusts to prioritise and plan local digital investment.

National Health Service organisations must ensure that all patients have equitable access to care, and that decisions or policies do not unfairly disadvantage people or lead to an increase in inequalities. All NHS organisations are legally obliged to not discriminate against patients or staff.

This means that a non-digital solution should be available for those patients who cannot or do not wish to engage digitally, and these non-digital routes must be available for all services provided by NHS organisations.

Aligned to the Equality Act 2010 and the Health and Social Care Act 2012, each 10-Year Health Plan policy, proposition, programme, proposal, or initiative in scope of public sector equality duties will undergo an Equality Impact Assessments and Equality and Healthcare Inequalities Impact Assessments.

Telecare is not a mandatory service for local authorities, but many choose to provide a telecare service due to its benefits. Local authorities are responsible for the contractual terms of telecare services that they provide. All public authorities are required to comply with current procurement legislation when procuring goods and services. This includes legislation relating to Data Protection and Consumer rights.

The Department is developing national telecare guidelines to give commissioners, providers, and users clarity about what good telecare looks like now and in the future. This will support local authorities to commission safe, reliable, and digitally compatible telecare services that safeguard vulnerable telecare users.

The Government is committed to enhancing provision and choice for older people in the housing market. The Department of Health and Social Care continues to work closely with the Ministry of Housing, Communities and Local Government to consider the recommendations from the Older People’s Housing Taskforce report.

Both departments are also working together on the development of the Government’s forthcoming long-term housing strategy.

More broadly, at the Spending Review, the Government announced £39 billion for a new Social and Affordable Homes Programme over ten years from 2026/27 to 2035/36. The programme has been designed to be flexible to support the greater diversity of supply needed in the housing market, including supported housing for older people.

The Government recognises that pharmacies are an integral ‘front door’ to the National Health Service, staffed by highly trained and skilled healthcare professionals.

In 2025/26, funding for the core community pharmacy contractual framework has been increased to £3.073 billion. This represents the largest uplift in funding of any part of the NHS, over 19% across 2024/25 and 2025/26. Additional funding is also available, for example for pharmacies delivering Pharmacy First consultations and flu and COVID-19 vaccinations.

The Department will shortly consult with Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27. As part of this we will consider financial pressures on the sector.

The Department continues to take forward work to explore redress for those affected by pelvic mesh and sodium valproate, which includes recommendations made by the Patient Safety Commissioner in the Hughes Report. We recognise the importance of these issues for all those affected. This remains a cross-Government policy area involving multiple organisations, and given the complexity of the issues involved, it is important we get this right.

I met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders. I have also written to the Patient Safety Commissioner regarding further steps to be taken to improve the lives of those affected by valproate and mesh. A copy of that letter is attached.

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. The sector is forecast to grow by £41 billion and create 100,000 jobs by 2030, supporting our ambition to lead Europe in life sciences by 2030.

The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.

The United Kingdom is a global leader in adopting biosimilar and generic medicines, which deliver major National Health Service savings and expand patient access to effective treatments sooner.

We are working with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE), and NHS England to understand forthcoming biosimilars and to ensure they reach the frontline efficiently. Through NHS England’s Best Value Biologicals Framework, clinicians start patients on the most cost‑effective biologics where appropriate, and switches are made swiftly and safely. This has already delivered £1.2 billion in savings over the past three years.

As set out in the 10‑Year Health Plan and Life Sciences Sector Plan, we are streamlining regulation, improving procurement, and reducing variation in uptake. NICE’s whole‑lifecycle approach ensures clinical pathways are regularly reviewed so that patients benefit as soon as cost‑effective generics and biosimilars become available, as seen in recent cancer treatments. These actions support timely access to effective off‑patent medicines and a sustainable, competitive market for the NHS.

The proposed amendments to the National Institute for Health and Care Excellence regulations were subject to a public consultation, which ran from 9 December 2025 to 13 January 2026. The Department is currently analysing consultation responses and will shortly finalise a statutory instrument (SI) to bring forward secondary legislation to amend the regulations.

The SI will be laid before Parliament and will be subject to the negative parliamentary procedure. The policy merits of the SI will be scrutinised by the Secondary Legislation Scrutiny Committee, in line with its terms of reference at the following link:

https://committees.parliament.uk/committee/255/secondary-legislation-scrutiny-committee/content/120278/slsc-terms-of-reference/

As is conventional, the SI will be laid before Parliament at least 21 days before coming into force to ensure Parliament has adequate time to consider it.

The Pharmacogenomics and Medicine Optimisation NHS Genomic Network of Excellence convened a multidisciplinary meeting in November 2023 to support an impact assessment of potential testing for APOE-4 for prediction of risk of adverse events for lecanemab and donanemab. This group considered the evidence for expanding genomic testing for the APOE gene variants, including to inform other dementia related risk factors and concluded that there was insufficient evidence to offer genomic testing for the APOE gene variants as part of routine dementia care, risk assessment, or to first degree relatives of those with an already identified APOE variant to inform risk estimates of developing future Alzheimer's disease.

The current Parliamentary Under-Secretary of State for Women's Health and Mental Health, Baroness Merron, the previous minister with responsibility for sodium valproate and pelvic mesh redress policy, held a roundtable with representatives of the sodium valproate patient groups in December 2024.

Since then, I met with relevant stakeholders at various parliamentary events. I also met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.

The Department continues to take forward work to explore redress for those affected by pelvic mesh and sodium valproate, which includes recommendations made by the Patient Safety Commissioner in the Hughes Report. We recognise the importance of these issues for all those affected. This remains a cross-Government policy area involving multiple organisations, and given the complexity of the issues involved, it is important we get this right. A timetable for a response has not yet been finalised.

I met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.

The Department does not hold information regarding the number of children that have been harmed by sodium valproate use during pregnancy, or those who have received a diagnosis of foetal valproate spectrum.

The National Disease Registration Service in NHS England collects and quality assures data about people with congenital conditions and rare conditions across the whole of England.

In the most recent official statistics on congenital conditions in England, the 2022 Congenital Condition Official Statistics Report, which contains information on congenital conditions detected in babies delivered in England between 1 January and 31 December 2022, as well as in previous publications of this series back to its inception in 2018, there were no foetus' or babies reported to have a diagnosis of fetal sodium valproate syndrome.

It is likely that while some of the individual conditions, for instance neural tube defects, cardiac, oro-facial clefts, and/or limb difference, that can be associated with this condition are recorded on the register, the overarching diagnosis of fetal sodium valproate syndrome may not yet be registered because fetal sodium valproate syndrome may take more than a year after birth to be confirmed as a diagnosis, so the number reported in any year is the minimum level in the population.

The National Disease Registration Service is assessing the feasibility and reliability of better ascertainment of fetal sodium valproate syndrome by linking the congenital condition register to primary care prescription data.

Though the Patient Safety Commissioner’s report covered England-only, we recognise that any response by the Government to the recommendations of the Hughes Report in England will likely have implications for the devolved administrations and their constituents.

Government officials are therefore working closely with officials across the United Kingdom in considering the recommendations in the Hughes Report. I recently met with my counterparts across the four nations and will continue productive engagement as we progress work in this area.

The Department continues to take forward work to explore redress for those affected by pelvic mesh and sodium valproate, which includes recommendations made by the Patient Safety Commissioner in the Hughes Report.

We recognise the importance of these issues for all those affected. This remains a cross-Government policy area involving multiple organisations, and given the complexity of the issues involved, it is important we get this right.

I also met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.

Everyone who has been harmed from sodium valproate has our deepest sympathies.

The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support, including co-ordination with non-health care services.

In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the NHS in Newcastle and Manchester. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, better coordination of care, and reduced reliance on emergency care. Findings from the pilot will inform future decisions on the commissioning of services, subject to funding.

In addition, we work closely with the Department for Education and across the Government to ensure co-ordination between health, education, and social care services for children and their families. The Health and Opportunity Missions of the Government highlight the importance of joined up working and integrated delivery.

The Government is currently developing the Tuberculosis National Action Plan for 2026 to 2031. The content of the plan, including any associated funding requirements, has not yet been finalised. Any proposals with financial implications will be subject to the usual cross‑Government processes, including agreement with HM Treasury. Details, with funding commitments, will be included when the plan is published.

Currently alcohol advertisements follow voluntary codes, regulated by the Advertising Standards Authority (ASA). The ASA’s Advertising Codes contain specific rules about how alcohol can be advertised, as they recognise the social imperative of ensuring that alcohol advertising is responsible.

The Department of Health and Social Care will continue to work with the Department for Digital, Culture, Media and Sport, as the lead Government department responsible for advertising, to consider if additional statutory restrictions on marketing and advertising are needed to reduce alcohol related harms.

The National Cancer Plan was published on the 4 February 2026.

The Department received more than 11,000 responses to a Call for Evidence alongside significant engagement with patients, families, carers, clinicians, researchers, cancer charities and voluntary groups.

Now that the National Cancer Plan is published, the Department, NHS England and the Cancer Alliances will continue to work together with partners across the healthcare landscape to ensure it is delivered, to transform cancer care and save lives.

The Government has committed to a clear accountability structure for the plan, where Cancer Alliances play a leading role to deliver it, working with local systems. A reformed National Cancer Board, jointly chaired by the Department and an independent representative, will track progress against the Plans commitments and provide regular updates to ministers. The plan includes tables at the end of each chapter, setting out when commitments should be delivered and which organisation will be responsible.

As set out in our 10-Year Health Plan for England: fit for the future, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever. As part of this, the Government committed to updating the standards behind the restrictions on advertising ‘less healthy’ food or drink products on television before 9:00pm and online at any time, as well as the restrictions on the promotion of ‘less healthy’ food and drink products by location and volume price by applying the new Nutrient Profiling Model (NPM).

The advertising and promotions restrictions currently rely on the outdated NPM 2004/05. The new NPM has been updated in line with the latest dietary advice from the United Kingdom’s Scientific Advisory Committee on Nutrition, particularly in relation to free sugar and fibre. Applying it to the restrictions will strengthen these policies by bringing more products of concern for children’s health into scope.

The Government published the new NPM on 27 January. Application of the new NPM to the advertising and promotions restrictions would be subject to a full public consultation and an impact assessment of the costs to businesses and intended health outcomes.

Integrated care boards (ICBs) are responsible for assessing local population need and commissioning appropriate diagnostic and treatment pathways for neurological conditions, including Tourette syndrome. While the Department has not undertaken a national assessment of provision across ICBs, we recognise the concerns raised about variation in diagnosis and support. To help address this, NHS England’s Getting It Right First Time (GIRFT) programme is working with ICBs to develop clear, consistent diagnostic and treatment pathways. The programme has appointed a clinical lead for children and young people's neurodevelopmental services, focusing on improving the assessment and management of Tourette syndrome.

The Independent Review into mental health conditions focuses on mental health conditions, ADHD and autism. Tourette’s is a neurological disorder and, therefore, it will be at the chair's discretion as to how far the review considers Tourette syndrome.

The Government recognises the harms associated with alcohol consumption and has taken crucial steps in the 10-Year Health Plan to support people to make healthier choices. There is a balance to be struck, and the Government continues to consider carefully what other measures might be needed to turn the tide on alcohol harms, while continuing to support economic growth.

Currently, alcohol advertisements follow voluntary codes, regulated by the Advertising Standards Authority (ASA). The ASA’s Advertising Codes contain specific rules about how alcohol can be advertised, as they recognise the social imperative of ensuring that alcohol advertising is responsible.

The Department of Health and Social Care continues to work with the Department for Digital, Culture, Media and Sport, as the lead Government department responsible for advertising, to consider if additional statutory restrictions on marketing and advertising are needed to reduce alcohol related harms.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions including amending the product information.

The MHRA has received a total of four United Kingdom reports through the Yellow Card scheme associated with the reaction term Post 5-Alpha Reductase Inhibitor Syndrome from 1 January 2019 up to and including 4 February 2026. The following table shows a yearly breakdown of reports associated with Post 5-Alpha Reductase Inhibitor Syndrome:

In addition, the following table shows a yearly breakdown of reports received by substance associated with Post 5-Alpha Reductase Inhibitor Syndrome:

Please note that each report may list more than one suspect drug. Therefore, the total number of reports received cannot be accurately derived from the figures presented in the above table.

It is important to note that anyone can report to the MHRA’s Yellow Card scheme and the recording of these reports in the Yellow Card database does not necessarily mean that the adverse reactions have been caused by the suspect drug. Many factors must be considered in assessing causal relationships, including temporal association, the possible contribution of concomitant medication, and the underlying disease. We encourage reporters to report suspected adverse reaction reports, as the reporter does not have to be sure of a causal association between the drug and the reactions, a suspicion will suffice.

The number of reports received cannot be used as a basis for determining the incidence of a reaction, as neither the total number of reactions occurring, nor the number of patients using the drug, is known.

The National Cancer Plan, published on 4 February 2026, will ensure that young cancer patients and their families receive better support, across diagnosis, treatment, and patient experience.

The Department has worked closely with the Children and Young People (CYP) Cancer Taskforce, to develop ambitious commitments on CYP cancer in the National Cancer Plan. The taskforce brought together experts across a range of fields to identify ways to improve outcomes and patient experience for young cancer patients and has been committed to ensuring the voices of key charity stakeholders and patients are included.

That’s why the Government assembled a Charity Sub-Group and Patient Experience Panel to ensure this expertise fed directly into the work of the taskforce.

The Government is committed to continuing its work with key cancer partners to deliver the commitments outlined in the National Cancer Plan.